Reuters logo
BRIEF-Verastem expands duvelisib development program to include peripheral T-cell lymphoma
September 6, 2017 / 11:13 AM / 19 days ago

BRIEF-Verastem expands duvelisib development program to include peripheral T-cell lymphoma

Sept 6 (Reuters) - Verastem Inc-

* Verastem expands duvelisib development program to include peripheral T-cell lymphoma

* Verastem Inc - ‍duvelisib receives fast track designation from FDA in PTCL; company to initiate a phase 2 clinical trial by year end 2017​

* Verastem Inc - verastem expects that phase 2 study of duvelisib will be conducted in both U.S. and Japan Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below